Research - Iovance (IOVA) is up 35% since we opened a position on news that the company’s BLA was going to be delayed (read thesis here). This was … Continue Reading
PremiumInsights - Essa Pharma (EPIX) is entering a second-gen drug, with a novel mechanism of action, into clinic for advanced prostate cancer The first-gen drug showed to … Continue Reading
PremiumInsights - On Friday, the companies announced success in two phase 3 studies of the IL-4/IL-13 antibody in AD, and now plan to file for approval later this year with the FDA.
Read nowInsights - All eyes were on Valeant Pharmaceuticals (VRX) Monday morning, but another ‘V’ name deserves credit for enabling some real science. Vertex Pharmaceuticals (VRTX) on Monday climbed aboard the gene editing bandwagon … Continue Reading
Read nowResearch - Regeneron’s (REGN) Praluent has been approved by the FDA, and the label essentially meets the Base Case scenario that we wrote about yesterday for Esperion … Continue Reading
PremiumInsights - Celgene (CELG) has placed its bet in the race to develop and market T cell therapies for oncology with a $1 billion infusion in cell therapy … Continue Reading
Read nowResearch - Trillium Therapeutics (TSX:TR) (OTC:SCTPF) is an immuno-oncology company developing novel cancer therapeutics. Trillium was founded in 2003 and went public on the Toronto exchange via … Continue Reading
Read now
